Skip to main content
  Sign In   Register

ePoster Presentations Proceedings »

Efficacy and tolerability of adjunctive perampanel in pediatric patients (aged 4–12 years) with inadequately controlled focal-onset seizures

Abstract Objective: To evaluate the efficacy, safety, and tolerability of adjunctive perampanel in children <12 years of age with refractory epilepsy. Methods: Medical records of 34 pediatric patients (aged 4–12 years) were reviewed. Efficacy was estimated by perampanel response rate at 4-, 8-, 12-, 24-, 36-, and 48-week follow-up evaluations. Adverse events (AEs) observed during the study were also recorded. Results: All patients exhibited uncontrolled focal-onset seizures; 64.71% of patients reported focal-onset seizures combined with generalized epilepsy. The mean (± standard deviation [SD]) age of enrolled patients was 7.21 (± 2.12) years, with a mean (± SD) age at seizure onset of 4.57 (± 2.59) years. The male-to-female ratio was 15:19. After the addition of perampanel, the mean responder rates at 4, 8, 12, 24, 36, and 48 weeks were 37.50% (12/32), 43.75% (14/32), 53.13% (17/32), 59.38% (19/32), 59.38% (19/32), and 62.07% (18/29). Two patients withdrew from perampanel treatment due to AEs in the first 2 weeks. AEs were reported by 44.12% (15/34) of patients, and the retention rates at 36 and 48 weeks were 94.12% (32/34) and 85.29% (29/34), respectively. Conclusion: Perampanel exhibited good efficacy, safety, and tolerability in the treatment of pediatric patients (aged 4–12 years) with refractory epilepsy. Personalized treatment and better baseline seizure control may increase the responder rate and retention rate of perampanel.
Keywords: Child, clinical efficacy, perampanel, refractory epilepsy, tolerability.

Si-jia Chu
Children’s Hospital of Soochow University
China

Ji-hong Tang
Children’s Hospital of Soochow University
China

 

 


®2002-2021 ICNApedia